“Today, against the respiratory syncytial virus (RSV) we can use new prevention possibilities, interfering with what is a disease that can be blocked in its most severe evolution: pneumonia and respiratory failure. While previously RSV was considered a very important pathogen in the pediatric population, recent works make it clear that it is also central to the elderly population which, according to statistics and numbers, is significantly affected. The vaccine we now have against the virus therefore becomes important.” Thus Roberto Parrella, president of the Italian Society of Infectious and Tropical Diseases (SIMIT) and director of the UOC Respiratory Infectious Diseases, Cotugno hospital in Naples, during an event organized by GSK in Rome.
“The RSV disease is transmissible and therefore the education and training of communities and the population must be given some attention – continued Parrella -. There is not much knowledge, especially in the elderly population, on what are the possible respiratory causes and we need to activate important communication systems to ensure that this type of pathology is made known”.
On Simit's commitment, the expert underlined that “the company is committed both to the training of its specialists and to communication and training activities for the general population”. Among its objectives, in fact, stands out that of “impacting political decision-makers and having the possibility of creating partnerships and alliances with scientific societies so that attention towards this type of pathology is known and carried forward as a strategy of prevention” because “we need – concludes Parrella – to also include this type of vaccine in the vaccination calendar”.
#Parrella #Simit #AntiRSV #blocks #severe #evolution #disease
